Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
CL

CLPTStockClearPoint Neuro Inc

Nasdaq Capital Market · Healthcare · US

$7.54 last close 2026-11-19
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment CLPT's does — no target price to set, unlike a price alert.

Near limit Ratio screen, 4 of 7 decided standards passing. AAOIFI, Dow Jones Islamic, MSCI Islamic M-Series, S&P Shariah are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant. What would change it

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-06
4 of 7 pass our own screen — the standards disagree
HTR non-permissible income 3.28%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟠 NOT YET
The main driver: lagging the market by 8.6%. More negatives than positives right now. The setup isn't ready — check...
Scores: 1 bullish / 2 bearish
46
of 100
Setup confidence — system conviction, not win probabilityD

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MOM · SCALP
Entry
$16.67
Stop
$16.50
Target
$17.01
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 100.0% aligned
VWAPPrice below VWAP ($8.10)
VolumeRelative volume 3.7× the 20-day average
Momentum10-day rate of change -21.6%
Overall readNOT YET

ClearPoint Neuro Inc (CLPT) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Price target
$21.50
+185.1% · 2 analysts
Institutional own.
55.0%
of shares
Momentum (10d)
-21.6%
rate of change
SMC grade
D · 46
100.0% aligned
3.28%
Non-permissible income — HTR, from filings (2025-12-31)
D · 46
SMC grade — 100.0% timeframe alignment
-21.6%
Rate of change (10d)
$21.50
Price target (+185.1%) · 2 analysts
55.0%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to CLPT’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $266.1M as of 2026-11-17. At the 2026-11-19 close it is about $248.7M (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 29.6% (27.7% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 18.9% (17.7% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 27.70% 30.00% Pass(2.3pp buffer)
Interest-bearing investments 17.71% 30.00% Pass(12.3pp buffer)
Non-permissible income 3.28% 5.00% Pass(1.7pp buffer)
Usmani Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 65.38% 33.00% Fail(32.4pp over)
Interest-bearing investments 41.79% 33.00% Fail(8.8pp over)
Non-liquid assets 51.10% at least 20.00% Pass(31.1pp above the floor)
Non-permissible income 3.28% 5.00% Pass(1.7pp buffer)
MSCI Fail 1 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 65.38% 33.33% Fail(32.0pp over)
Cash + interest-bearing securities 41.79% 33.33% Fail(8.5pp over)
Accounts receivable 48.90% 33.33% Fail(15.6pp over)
Non-permissible income 3.28% 5.00% Pass(1.7pp buffer)
FTSE Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 45.10% 33.33% Fail(11.8pp over)
Cash + interest-bearing securities 41.79% 33.33% Fail(8.5pp over)
Accounts receivable 48.90% 50.00% Pass(1.1pp buffer)
Non-permissible income 3.28% 5.00% Pass(1.7pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 15.82% 33.00% Pass(17.2pp buffer)
Cash + interest-bearing securities 10.11% 33.00% Pass(22.9pp buffer)
Accounts receivable 1.72% 33.00% Pass(31.3pp buffer)
Non-permissible income 3.28% 5.00% Pass(1.7pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 18.95% 33.00% Pass(14.1pp buffer)
Cash + interest-bearing securities 12.11% 49.00% Pass(36.9pp buffer)
Accounts receivable 2.06% 49.00% Pass(46.9pp buffer)
Non-permissible income 3.28% 5.00% Pass(1.7pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 18.95% 33.33% Pass(14.4pp buffer)
Cash + interest-bearing securities 12.11% 33.33% Pass(21.2pp buffer)
Accounts receivable 14.17% 49.00% Pass(34.8pp buffer)
Non-permissible income 3.28% 5.00% Pass(1.7pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

FTSE Shariah Global Equity Index Series (% of total assets)receivables ratio 1.1pts
AAOIFI Standard 21 (% of market cap)non permissible income ratio 1.7pts
Usmani (% of total assets)non permissible income ratio 1.7pts
Usmani (% of total assets)debt ratio 32.4pts
MSCI Islamic Index (% of total assets)debt ratio 32.0pts
MSCI Islamic Index (% of total assets)receivables ratio 15.6pts

The numbers the ratios are built from

Read from CLPT's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $37.0M 2025-12-31 Revenues
Interest-bearing debtShort and long-term borrowings $50.8M 2026-09-30 LongTermDebt
Cash and interest-bearing securitiesCash, equivalents and marketable securities $47.1M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $112.7M 2026-09-30 Assets
Market capDenominator for AAOIFI $266.1M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $334.1M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $396.3M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $1.2M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2025-12-31. Screened 2026-11-17.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$112.7M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$50.8M
    LongTermDebt · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$47.1M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-09-30
  • Receivables$8.0M
    AccountsReceivableNetCurrent · balance sheet as of 2026-09-30
  • Revenue$37.0M
    Revenues · income statement as of 2025-12-31
  • Interest income (non-permissible)$1.2M
    InvestmentIncomeInterest · income statement as of 2025-12-31
  • Market cap$266.1M
    Market-data quote at screen time, 2026-11-17 · not a filing figure, so no link

What changed, and when

Verdict history for CLPT. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-17 Unverified → Fail filing re-screen
  • 2026-11-17 Unverified → Pass filing re-screen

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-17.

Within 3 points of the line

AAOIFI, Dow Jones Islamic, MSCI Islamic M-Series, S&P Shariah are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant.

The ratios that move with the share price

AAOIFI's debt ratio is $73.7M debt (operating leases included, as the screen counts it) over a market cap of $266.1M (as of 2026-11-17), 27.7% against a 30% line.

At the 2026-11-19 close the market cap is about $248.7M (the stored cap moved by the share price since), so this ratio would read 29.6%; the line is -1% from there. The published status changes only when the company is re-screened.

It would fail if the market cap fell to $245.7M (-8%), about $7.66 a share against $8.30 implied by the screen's own figures.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing).

At the screen's market cap, debt would have to rise by $6.1M to reach the line.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).

AAOIFI's investments ratio is $47.1M cash and interest-bearing investments over a market cap of $266.1M (as of 2026-11-17), 17.7% against a 30% line.

At the 2026-11-19 close the market cap is about $248.7M (the stored cap moved by the share price since), so this ratio would read 18.9%; the line is -37% from there. The published status changes only when the company is re-screened.

It would fail if the market cap fell to $157.0M (-41%), about $4.90 a share against $8.30 implied by the screen's own figures.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing).

At the screen's market cap, cash and interest-bearing investments would have to rise by $32.7M to reach the line.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Medical Devices listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
ABTAbbott Laboratories $201.9B —
SYKStryker Corp. $125.7B —
MDTMedtronic Plc $117.8B —
BSXBoston Scientific Corp. $71.0B —
EWEdwards Lifesciences Corp $52.2B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold CLPT

2 of the 202 funds whose filed holdings we currently hold own CLPT shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns CLPT.

You may already own it

Widely held U.S. index funds. If you own one, you own CLPT through it. None of them is a Shariah fund; the last column is our look-through of each.

FundCLPT in fundFund compliant by weight
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00% 54%

Sorted by CLPT’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names CLPT once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding CLPT
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $4M 0.0% 2026-09-30
Israel Englander Millennium Management $3M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

19.4316.4613.4810.517.532025-11-192026-05-222026-11-19

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
7.07
S2
7.34
S1
7.52
PIVOT
7.79
R1
7.97
R2
8.24
R3
8.42

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
5.85 – 9.97
±26.06% from 7.91, made 2026-11-17 · resolves 2026-11-24
STRONG SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)31.80NEUTRAL
Stochastic %K (14)0.92BUY
CCI (20)-134.31BUY
Williams %R (14)-99.08BUY
MACD (12,26,9)-0.07SELL
ROC (10)-13.35SELL
Momentum (10)-1.16SELL
EMA (10)8.35SELL
SMA (10)8.41SELL
EMA (20)8.95SELL
SMA (20)9.12SELL
EMA (30)9.50SELL
SMA (30)9.26SELL
EMA (50)10.46SELL
SMA (50)10.77SELL
EMA (100)11.80SELL
SMA (100)13.05SELL
EMA (200)12.27SELL
SMA (200)12.60SELL

About ClearPoint Neuro Inc

Healthcare · Medical Devices

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

clearpointneuro.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-08-25

MOM
Type · SCALP
16.67
Entry
16.50
Stop
17.01
Target
LOSS
Outcome · exit 16.50 (-1.02%)

Stop 16.50 Now 7.54 Target 17.01

Verdict

🟠 NOT YET

The main driver: lagging the market by 8.6%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.

Scores: 1 bullish / 2 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 64
⏰ 4H BEARISH 40
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-21.6%
Rate of change (10d)
3.7×
Volume vs its 20-day average
-0.75
MACD (no fresh cross)
$7.79
Volume POC (today)
$7.59 – $7.83
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.